Evaluating statins for treating Moyamoya disease

Study on Evaluating the Effectiveness of Statins in the Treatment of Moyamoya Disease

This study is testing if statin medication can help improve the condition and outcomes for people with Moyamoya disease.

Quick facts

• Study type: Observational
• Enrollment: 330 (estimated)
• Ages: 18 Years to 60 Years
• Sex: All
• Sponsor: Beijing Tiantan Hospital (other)
• Locations: 1 site (Beijing, China)
• Trial ID: NCT06817434 on ClinicalTrials.gov

What this trial studies

This study investigates the effectiveness of statins in treating Moyamoya disease using multimodal magnetic resonance imaging. It involves patients who have been diagnosed with the condition and are receiving either revascularization or conservative management. The study aims to assess the impact of statin therapy on disease progression and patient outcomes through imaging follow-ups.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 and older diagnosed with Moyamoya disease who meet specific imaging and clinical criteria.

Not a fit: Patients with conditions such as atherosclerosis, autoimmune diseases, or those under 18 years old may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide new insights into the management of Moyamoya disease and improve treatment options for patients.

How similar studies have performed: While the use of statins in cerebrovascular diseases has been explored, this specific application in Moyamoya disease is relatively novel and not extensively tested.

Eligibility criteria

Inclusion Criteria:

1. The imaging examination meets the diagnostic criteria for moyamoya disease;
2. Sign the informed consent form;
3. Age ≥18 years old;
4. Baseline mRS score ≤2 points;
5. The patient receives revascularization/conservative treatment;
6. There is at least 1 imaging follow-up result.

Exclusion Criteria:

1. Patients with atherosclerosis, autoimmune diseases, meningitis, Down syndrome, cranial trauma, or those who have undergone radioactive head irradiation, as these conditions may lead to secondary cerebrovascular disease and contribute to the development of Moyamoya syndrome;
2. Individuals under the age of 18;
3. Participants who refuse to take part in this study;
4. Pregnant patients;
5. Those with concurrent intracranial aneurysms, cerebrovascular malformations, brain tumors, or hydrocephalus;
6. A history of stroke occurring more than three months prior to the diagnosis of Moyamoya disease;
7. Individuals with a history of coronary heart disease or previous cardiovascular and cerebrovascular surgical interventions, including cerebral revascularization, intracranial artery stent implantation, carotid artery stenting, endarterectomy, coronary artery bypass grafting, or coronary stent implantation;
8. Allergies to contrast media;
9. Patients with missing imaging data or whose image quality cannot be analyzed;
10. Individuals who refuse or are unable to undergo imaging follow-up;
11. Patients receiving other types of lipid-lowering drug treatments.

Where this trial is running

Beijing, China

• Beijing Tiantan Hospital — Beijing, China, China (RECRUITING)

Study contacts

• Study coordinator: Qian Zhang

Conditions: Moyamoya Disease